Health insurer stocks slide as final Medicare Advantage rates disappoint

Health insurer stocks slide as final Medicare Advantage rates disappoint


Signage is displayed on a Humana Inc. office building in Louisville, Kentucky, U.S., on Saturday, Feb. 2, 2019. Humana is scheduled to release earnings figures on February 6.

Luke Sharrett | Bloomberg | Getty Images

Shares of U.S. health insurers fell on Tuesday after the Biden administration didn’t boost payments for private Medicare plans as much as the insurance industry and investors had hoped. 

Shares of CVS Health fell more than 6% on Tuesday, while UnitedHealth Group‘s stock slid roughly 6%. Shares of Elevance Health dropped 2% and Centene‘s stock fell nearly 5%. 

Meanwhile, Humana‘s stock fell more than 10%. The health-care giant is far more dependent on those private Medicare plans, known as Medicare Advantage, than its rivals. 

The announcement puts more pressure on insurers already grappling with high medical costs and uncertainty around claims processing after the cyberattack on UnitedHealth Group’s tech unit. It also deals a blow to Medicare Advantage businesses, which have long been driven growth and profits for the insurance industry.

The Centers for Medicare and Medicaid Services said late Monday that government payments to Medicare Advantage plans are expected to rise 3.7% year over year. That is effectively a 0.16% decline after stripping out certain assumptions baked into that rate, according to insurers and analysts. 

That final rate is unchanged from an earlier proposal in January. Typically, the federal agency raises that rate from its initial proposal. 

The closely watched rate determines how much insurers can charge for monthly premiums and plan benefits they offer, and ultimately, their profits.

Medicare Advantage is a privately run health insurance plan contracted by Medicare. More than half of Medicare beneficiaries are enrolled in such plans, enticed by lower monthly premiums and extra benefits not covered by traditional Medicare, according to health policy research firm KFF. 



Source

Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports
Health

Trump reaches deal with AstraZeneca to lower U.S. drug prices, MSNBC reports

U.S. President Donald Trump participates in a bilateral meeting with Finland’s President Alexander Stubb (not pictured), in the Oval office at the White House in Washington, D.C., U.S., Oct. 9, 2025. Nathan Howard | Reuters The Trump administration and AstraZeneca have reached an agreement for the U.K.-based pharmaceutical giant to cut drug prices in the […]

Read More
At-risk teens and AI chatbot crisis: ‘You need to know what’s going on,’ warns Talkspace CEO
Health

At-risk teens and AI chatbot crisis: ‘You need to know what’s going on,’ warns Talkspace CEO

Talkspace has grown to be one of the largest online therapy platforms in the U.S., covering an estimated market of 200 million Americans. As the mental health platform has grown, it has also pioneered new ways to reach people in need of help with mental health issues including trauma, depression, addiction, abuse and relationships, and […]

Read More
Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers
Health

Healthy Returns: Amgen joins a growing list of drugmakers selling directly to consumers

The Amgen headquarters in Thousand Oaks, California. Eric Thayer | Bloomberg | Getty Images A version of this article first appeared in CNBC’s Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions. Drugmakers are increasingly using telehealth platforms to sell their medicines directly to patients […]

Read More